Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GCL vs SLXN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GCL Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–2 Matrix Metrics)

GCL Overall Winner 6-Pillar Tally: GCL 5 – 1 SLXN Matrix Metrics: GCL 6 – 2 SLXN

As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over Silexion Therapeutics Corp (SLXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas SLXN carries 23.9/100 (STRONG SELL) at $1.76 (N/M Forward P/E, 0.0% operating margin).

  • Defensive Composite Rating Caution: Although GCL compares more favorably head-to-head, both GCL (31.6/100 SELL) and SLXN (23.9/100 STRONG SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6); meanwhile SLXN is in a Breakdown options structure phase (RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GCL vs SLXN
GCL NASDAQ Head-to-Head Winner
GCL Global Holdings Ltd Ordinary Shares
Services-Prepackaged Software
$1.16
-2.93% 1D
Market Cap $153.0M
TTM Revenue $239M
Forward P/E N/M
Beta / 30D Vol 1.52β · 75% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 50.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (22.9% over 20 days), RSI 71
RSI-14: 70.6 · SMA20: $0.98 · SMA50: $0.82
SLXN NASDAQ
Silexion Therapeutics Corp Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.76
-11.11% 1D
Market Cap $1.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 28.94β · 9931% Vol
Unified Composite Score
23.9 / 100 STRONG SELL
Tech 50.0 Fund 29.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (13.9% over 20 days), RSI 63
RSI-14: 63.5 · SMA20: $0.60 · SMA50: $0.42

6-Pillar Scorecard Institutional Category Breakdown (GCL 5 – 1 SLXN)

Columns: Metric · GCL · SLXN
1. Valuation Multiples GCL
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.6x N/M
2. Growth & Scale GCL
Revenue Growth (YoY) +53.8% +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) $239M N/A
Market Cap $153.0M $1.3M
3. Profitability & Quality SLXN
Gross Margin 10.3% N/A
Operating Margin -5.5% 0.0%
Net Profit Margin -10.5% 0.0%
Return on Equity (ROE) -67.3% -897.5%
4. Balance Sheet & Cash Flow GCL
Cash Generation (TTM) -$12M EBITDA N/A
Cash Flow Margin -4.9% EBITDA Mgn N/A
Net Cash / Leverage $0.29 Book/Sh · -67.3% ROE $1.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GCL
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat GCL
OpEx & R&D Intensity 15.8% of Rev ($38M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Electronic Gaming & Multimedia Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GCL (6) vs SLXN (2)
Institutional Metric GCL SLXN Criterion Row Edge
Market Capitalization
Scale
$153.0M $1.3M Larger Scale GCL
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+53.8% +0.0% Higher Growth GCL
Operating Margin (TTM)
Profitability
-5.5% 0.0% Higher Margin SLXN
Net Profit Margin
Profitability
-10.5% 0.0% Higher Margin SLXN
Return on Equity (ROE)
Capital Efficiency
-67.3% -897.5% Higher ROE GCL
52-Week Range Position
Momentum
57% ($0–$2) 31% ($0–$5) Stronger Trend GCL
Beta / 30D Volatility
Risk Regime
1.52β · 75% Vol 28.94β · 9931% Vol Lower Realized Risk GCL
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 23.9 / 100 (STRONG SELL) Higher Composite GCL
Trailing 12M Revenue (USD)
Operating Scale
$239M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
10.3% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M EBITDA ($0.29 Book/Sh · -67.3% ROE) N/A ($1.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLXN +1017.17 pp
GCL: +33.16% · SLXN: +1050.33%
3M Horizon SLXN +219.43 pp
GCL: +101.42% · SLXN: +320.85%
6M Horizon SLXN +379.81 pp
GCL: +163.7% · SLXN: +543.51%
1Y Horizon GCL +10.28 pp
GCL: -28.4% · SLXN: -38.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GCL vs SLXN. Trailing 12-month operating profitability (GCL -5.5% vs SLXN 0.0%) and valuation multiples (GCL N/M vs SLXN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$239M
Gross Margin10.3%
Op. Margin-5.5%
ROE / Fwd P/E-67.3% · N/M
SLXN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-897.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLXN BREAKDOWN
109d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLXN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GCL Moat Profile Cyclical / Execution-Driven Positioning
Electronic Gaming & Multimedia Operator
Competes within the Electronic Gaming & Multimedia value chain with $153.0M market capitalization and -5.5% operating margin.
OpEx & R&D Reinvestment 15.8% of Rev ($38M)
90D Engineering Disclosures 0 Published
SLXN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GCL vs SLXN Key Questions & Quantitative Answers

As of Nov 16, 2026, GCL Global Holdings Ltd (GCL) is the stronger overall head-to-head candidate over Silexion Therapeutics Corp (SLXN) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). GCL carries a Unified Composite Score of 31.6/100 (SELL) at $1.16 (N/M Forward P/E, -5.5% operating margin), whereas SLXN carries 23.9/100 (STRONG SELL) at $1.76 (N/M Forward P/E, 0.0% operating margin). Defensive Composite Rating Caution: Although GCL compares more favorably head-to-head, both GCL (31.6/100 SELL) and SLXN (23.9/100 STRONG SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: GCL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 70.6); meanwhile SLXN is in a Breakdown options structure phase (RSI 63.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GCL leads the Growth & Scale pillar: GCL posts +53.8% YoY revenue growth and N/A YoY earnings growth on $239M TTM revenue (10.3% gross margin, -5.5% operating margin), compared with SLXN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, GCL generates $239M in USD-normalized revenue versus N/A for SLXN. In operating R&D and SG&A reinvestment, GCL deploys 15.8% of Rev ($38M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLXN.

GCL screens cheaper on headline valuation multiples. GCL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.6x EV/Revenue (-4.9% EBITDA margin), whereas SLXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GCL (-67.3% ROE) versus SLXN (-897.5% ROE) capital efficiency.

In options market volatility and institutional positioning, GCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 75% Vol realized risk). By comparison, SLXN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (28.94β · 9931% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.